712 North Inc. Announces USPTO Grant of New Patent for Innovative OMA1 Protease Modulators

May 28, 2024 — 712 North Inc., a pre-clinical pharmaceutical company specializing in mitochondrial medicine, announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent entitled “Pyranone compounds useful to modulate OMA1 protease.”

This milestone reinforces 712 North’s commitment to building a robust chemical library of first-in-class mitochondrial modulators. 

“The issuance of this patent for our pyranone series further validates our unique approach to mitochondrial quality control,” said Dr. Marcel V. Alavi, CEO of 712 North. “By targeting the OMA1 protease, we are addressing a fundamental biological switch that can determine cell fate.”

712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases.

For more information, please visit www.712north.com.